CA
CASI Pharmaceuticals, Inc.
CASI · NASDAQ
$0.15 +3.08% (+$0.00)
Market Cap $2.25M
P/E Ratio -
Div. Yield -
ROE 358.32%
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 0.08x
P/FCF N/A
P/FFO N/A
Growth
78 /100
Growing Book val. growth 15.16%
Rev. growth 118.52%
FCF growth N/A
Profitability
16 /100
Weak FCF margin 0.00%
Op. margin 167.98%
Gross margin 35.80%
Quality
44 /100
Average Asset turnover 1.10x
ROA 201.86%
ROIC 1,210.78%
Debt
50 /100
Moderate Int. coverage -31.98x
Net debt/EBITDA -0.34x
Current ratio 0.30x
Stability
48 /100
Moderate Profitable years 0
EPS volatility 25.29%
Beta 0.89x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o CASI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David A. Cory
Employees
233
Headquarters
Beijing